Bintai Kinden Corp’s partner Generex Biotechnology Corp has signed a framework agreement for the development and commercialisation of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China with the Chinese Center for Disease Control and Prevention (China CDC), Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd. Generex will receive upfront development fees and back-end licensing payment under the framework agreement.

http://www.theedgemarkets.com/article/mr-diy-...tion-group